- 专利标题： HERITABLE EPIGENETIC MODIFICATIONS AS MARKERS OF CHEMOTHERAPY EXPOSURE
-
申请号： US17870886申请日： 2022-07-22
-
公开(公告)号： US20220364176A1公开(公告)日： 2022-11-17
- 发明人: Michael K. Skinner , Margarett Shnorhavorian
- 申请人： Washington State University , Seattle Children's Hospital DBA Seattle Children's Research Institute
- 申请人地址： US WA Pullman; US WA Seattle
- 专利权人： Washington State University,Seattle Children's Hospital DBA Seattle Children's Research Institute
- 当前专利权人： Washington State University,Seattle Children's Hospital DBA Seattle Children's Research Institute
- 当前专利权人地址： US WA Pullman; US WA Seattle
- 主分类号： C12Q1/6883
- IPC分类号： C12Q1/6883
摘要：
Provided herein are epigenetic modifications that are associated with prior exposure to chemotherapy agents. In particular, differential DNA methylation regions (DMRs) that are characteristic of, and can thus be used to identify and/or treat, a male subject who has undergone chemotherapy are provided. The DMRs are used to screen for pregnancy complications, infertility, and passage of heritable mutations to an infant.
信息查询
